KRUTMANN JEAN has a total of 14 patent applications. Its first patent ever was published in 1998. It filed its patents most often in United States, Germany and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are BEIJING CENTURY BIOCOM PHARM, BASIC ROBERT and TOPOKINE THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | Germany | 4 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Specific use of cosmetics |
# | Name | Total Patents |
---|---|---|
#1 | Krutmann Jean | 14 |
#2 | Grether-Beck Susanne | 4 |
#3 | Stege Helger | 4 |
#4 | Haendeler Judith | 1 |
#5 | Schwarz Thomas | 1 |
#6 | Grewe Markus | 1 |
#7 | Lentzen Georg | 1 |
Publication | Filing date | Title |
---|---|---|
US2010202987A1 | Preparation for improving the protection of human cells, especially cells of the human skin, from the harmful influences of oxidative noxae and uv radiation | |
DE10359153A1 | Use of specific triterpene derivatives for systemic treatment of light-induced dermatatis and the long-term consequences of exposure to ultra-violet light | |
DE10037046A1 | Use of N-oleoylethanolamine to treat psoriasis | |
DE10031457A1 | Use of O-beta-hydroxyethylrutoside or its aglycon for the systemic treatment and prophylaxis of UV-induced dermatoses and undesirable long-term consequences of UV radiation | |
DE19837230A1 | Use of neurotrophin-4 as a therapeutic agent, especially for treating melanoma |